Committee for Advanced Therapies (CAT)
Minutes of the meeting on 19-21 April 2023

Chair: Ilona Reischl; Vice-Chair: Carla Herberts

Disclaimers

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, these minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
Table of contents

1. Introduction......................................................................................................................... 5
1.1. Welcome and declarations of interest of members, alternates and experts................. 5
1.2. Adoption of agenda ........................................................................................................ 5
1.3. Adoption of the minutes ............................................................................................. 5

2. Evaluation of ATMPs ........................................................................................................ 5
2.1. Opinions ....................................................................................................................... 5
2.2. Oral explanations ....................................................................................................... 5
2.2.1. Lenadogene nolparvovec - Orphan - EMEA/H/C/005047 ............................................. 5
2.3. Day 180 list of outstanding issues ....................................................................... 6
2.4. Day 120 list of questions ....................................................................................... 6
2.5. Day 80 assessment reports ...................................................................................... 6
2.5.1. Exagamglogene autotemcel - PRIME - Orphan - EMEA/H/C/005763 ................. 6
2.6. Update on ongoing initial applications .................................................................. 6
2.7. New applications .................................................................................................... 7
2.8. Withdrawal of initial marketing authorisation application .................................. 7
2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004 ........................................................................................................ 7
2.10. Companion diagnostics .......................................................................................... 7
2.10.1. Initial consultation .............................................................................................. 7
2.10.2. Follow-up consultation ..................................................................................... 7
2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 ............................................................. 7
2.11.1. Abecma - idecabtagene vicleucel - Orphan - EMEA/H/C/004662/II/0027 .......... 7
2.11.2. Alofisel - darvadstrocel - Orphan - EMEA/H/C/004258/II/0045/G .................. 8
2.11.3. Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0059 ................. 8
2.11.4. ROCTAVIAN - valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/II/0004/G .... 8
2.11.5. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0003 ................................................................................................................................. 8
2.11.6. Abecma – idecabtagene vicleucel – Orphan - EMEA/H/C/PSUSA/00010954/202209 .... 9
2.12. Extension applications............................................................................................... 9
2.13. Other Post-Authorisation Activities ....................................................................... 9
2.13.1. Abecma - idecabtagene vicleucel - Orphan - EMEA/H/C/004662/R/0029 ........... 9
2.13.2. CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/ME/007.1 ....... 9
2.13.3. Ebvallo - tabelecleucel - Orphan - EMEA/H/C/004577/REC/006 ..................... 10
2.13.4. ROCTAVIAN - valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/R/0003 ........ 10
2.14. GMP and GCP inspections requests ..................................................................... 10
3. Certification of ATMPs 10
3.1. Opinion ................................................................................................................. 11
3.2. Day 60 Evaluation Reports .................................................................................... 11
3.3. New Applications .................................................................................................. 11

4. Scientific Recommendation on Classification of ATMPs 11
4.1. New requests – Appointment of CAT Coordinator ................................................. 11
4.1.1. Living human adult allogeneic immunomodulatory progenitor (iMP) cells ............. 11
4.1.2. Allogeneic viable natural killer (NK) cells CD56+ CD3- ................................................. 11
4.1.3. Recombinant Adeno-associated virus serotype 9 vector containing the human-lysosome-associated membrane glycoprotein 2 isoform B transgene ......................................................... 11
4.2. Day 30 ATMP scientific recommendation .............................................................. 12
4.2.1. Ixoberogene soroparvovec (genetically engineered, replication-incompetent adeno-associated virus vector comprising the AAV.7m8 capsid proteins, carrying a version of complementary deoxyribonucleic acid for aflibercept) ........................................................................ 12
4.2.2. Ex vivo fused allogeneic human myoblasts (MB-N) with autologous human myoblast (MB-ALS) ............................................................................................................................. 12
4.2.3. Ex vivo fused allogeneic human myoblasts (MB-N) with autologous human bone marrow derived mesenchymal stem cells (MSC-ALS) ................................................................. 12
4.2.4. Ex vivo fused allogeneic human mesenchymal stem cell (MSC-N) with autologous human myoblast (MB-ALS) ................................................................. 12
4.2.5. Ex vivo fused allogeneic human myoblasts (MB-N1) with allogeneic human myoblasts (MB-N2) ............................................................................................................................. 13
4.2.6. Helper-dependent adenovirus vector coding for interleukin-1 receptor antagonist ........ 13
4.2.7. Autologous CD34+ cells from mobilised peripheral blood .............................................. 13
4.2.8. Biotinylated cultured reticulocytes, cultured from haematopoietic stem cells ................... 13
4.3. Day 60 revised scientific recommendation (following list of questions) ............... 13
4.3.1. Autologous chondrocytes cultured in hyaluronan-derived scaffold .............................. 13
4.4. Finalisation of procedure ...................................................................................... 14
4.4.1. Lyophilised supernatant of a pathogen inactivated and gamma sterilised platelet lysate ... 14
4.4.2. Autologous intestinal organoid derived from adult stem cells from intestinal epithelial tissue14
4.5. Follow-up and guidance ........................................................................................ 14

5. Scientific Advice 14
5.1. New requests - appointment of CAT Rapporteurs ................................................. 14
5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers ............ 14
5.1.2. Scientific advice procedures starting at the next SAWP meeting ................................. 15
5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs ................................. 15
5.3. Finalisation of D70 procedures – feedback from the discussion meeting ............... 15
5.4. Final Advice Letters for procedures finalised the previous month ......................... 15
## 6. Pre-Authorisation Activities 15

6.1. Paediatric investigation plans

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

### 6.3.1. Month 0 - Start of the procedure

### 6.3.2. Month 1 – Discussion of eligibility

### 6.3.3. Month 2 – Recommendation of eligibility

### 6.3.4. Ongoing support

## 7. Organisational, regulatory and methodological matters 16

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

7.1.2. Vote by proxy

7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Sweden presidency, 4 and 5 May 2023, Upsala (Sweden)

7.1.4. New timeschedule layout

7.2. Coordination with EMA Scientific Committees

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. PRIME implementation of 5-year review recommendations – 2023 pilot features and guidance updates

7.3.2. Joint EU GCP inspectors-clinical assessors virtual workshop, 26 June 2023

7.3.3. Re-organisation of Biologics Working Party (BWP)

7.4. Cooperation with the EU regulatory network

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)

7.6. CAT work plan

7.6.1. Guideline of quality, non-clinical and clinical requirements for investigational ATMPs in clinical trials

7.7. Planning and reporting

7.8. Others

7.8.1. CAT stakeholder meeting 2023

7.8.2. Euroscan – International HealthTechScan (i-HTS)

7.8.3. European Health and Digital Executive Agency (HaDEA)

## 8. Any other business 19

8.1. New Expert Management Tool

## 9. List of participants 19

## 10. Explanatory notes 23
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

The Chairperson opened the meeting by welcoming all participants. The meeting was held remotely.

In accordance with the Agency’s policy on handling of declarations of interests of scientific committees’ members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and on the topics in the agenda of the current meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants for agenda topics was identified.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. **Adoption of agenda**

The CAT agenda for 19-21 April 2023 meeting was adopted.

1.3. **Adoption of the minutes**

The CAT minutes for 22-23 March 2023 meeting were adopted with one amendment to agenda point 4.2.3.

2. **Evaluation of ATMPs**

2.1. **Opinions**

No items

2.2. **Oral explanations**

2.2.1. **Lenadogene nolparvovec - Orphan - EMEA/H/C/005047**

GenSight Biologics S.A.; Treatment of vision loss due to Leber hereditary optic neuropathy (LHON)
Scope: Oral explanation

**Action:** for discussion


The Rapporteur highlighted the outstanding major objections (MO).

After the preparatory discussion, the CAT chair welcomed a patient with LHON.

During the oral explanation, the applicant mainly focused on the clinical MO.

The patient, on questions from the CAT, provided his view of the description of the patient population and the clinical relevance of the effect claimed by the applicant.

In absence of the applicant and the patient, CAT discussed the outcome of the assessment of the responses to the list of outstanding issues and the additional information and justifications provided during the oral explanation. CAT agreed that the data are not sufficient for granting a marketing authorisation. A trend vote was taken, confirming that a majority of CAT members do not agree that a positive opinion can be adopted.

Post-meeting note: after debriefing, the applicant decided to withdraw the marketing authorisation application. The withdrawal letter and the withdrawal EPAR will be published on the EMA website.

### 2.3. Day 180 list of outstanding issues

No items

### 2.4. Day 120 list of questions

No items

### 2.5. Day 80 assessment reports

#### 2.5.1. Exagamglogene autotemcel - PRIME - Orphan - EMEA/H/C/005763

Vertex Pharmaceuticals (Ireland) Limited; Treatment of transfusion-dependent β-thalassemia and sickle cell disease

Scope: Day 80 assessment report

**Action:** for information

The information was noted.

### 2.6. Update on ongoing initial applications

No items
2.7. New applications

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. Companion diagnostics

2.10.1. Initial consultation

2.10.1.1. In vitro diagnostic medical device - EMEA/H/D/006255

Indicated as an aid in the selection of adult haemophilia A patients for whom valoctocogene roxaparvovec treatment is being considered

Scope: Request for supplementary information

Action: for adoption

The Rapporteur presented the assessment of suitability of the companion diagnostic (CDx) to screen patients to be treated with Roctavian.

It was clarified that the assessment of the performance of the assay is under the responsibility of the Notified Body; also, the wording of the intended use, e.g. “aid in the selection of ...” which is well described as part of the ‘Instructions for Use (IfU)’ document, is in line with the standard wording approved by FDA, and outside of the remit of this procedure.

CAT discussed the request for supplementary information (RSI): one additional question was included. The RSI was adopted.

2.10.2. Follow-up consultation

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Abecma - idecабtagene vicleucel - Orphan - EMEA/H/C/004662/II/0027

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Rune Kjeken
Scope: Quality, Opinion

**Action:** for adoption

Request for supplementary information adopted on 24.03.2023.

The opinion was adopted.

### 2.11.2. Alofisel - darvadstrocel - Orphan - EMEA/H/C/004258/II/0045/G

Takeda Pharma A/S

Rapporteur: Lisbeth Barkholt

Scope: Quality, Opinion

**Action:** for adoption

The opinion was adopted.

### 2.11.3. Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0059

Amgen Europe B.V.

Rapporteur: Maija Tarkkanen

PRAC Rapporteur: Gabriele Maurer

Scope: Pharmacovigilance, Opinion (PRAC procedure)

Submission of an updated RMP version 10 in order to update and reclassify identified risk of 'disseminated herpetic infection' based on the cumulative assessment of literature review, and MAH Global Safety Database, and to remove studies 20180062 and 20180099 from Planned and Ongoing Studies from the list of Pharmacovigilance Plan studies in Annex II.

**Action:** for adoption

Request for supplementary information adopted on 20.01.2023.

The opinion was adopted.

### 2.11.4. ROCTAVIAN - valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/II/0004/G

BioMarin International Limited

Rapporteur: Violaine Closson Carella

Scope: Quality, Opinion

**Action:** for adoption

The opinion was adopted.

### 2.11.5. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0003

Bristol-Myers Squibb Pharma EEIG
Rapporteur: Concetta Quintarelli

**Scope:** Quality, Clock stop extension

**Action:** for adoption

The clock stop extension was agreed.

### 2.11.6. Abecma – idecabtagene vicleucel – Orphan - EMEA/H/C/PSUSA/00010954/202209

Bristol-Myers Squibb Pharma EEIG

**Rapporteur:** Rune Kjeken, **Co-Rapporteur:** Heli Suila, **PRAC Rapporteur:** Ulla Wändel Liminga

**Scope:** variation following PSUR assessment: update of section 4.4 of the SmPC to add warning information on Parkinsonism and to mention it in the footnotes of the table in section 4.8 of the SmPC for the SOC “Nervous system disorders” (PRAC led procedure)

**Action:** for information

CAT noted the outcome of the PRAC-led variation to add information on Parkinsonism in the SmPC. The wording is aligned to that included in the SmPC for Carvykti.

### 2.12. Extension applications

No items

### 2.13. Other Post-Authorisation Activities

#### 2.13.1. Abecma - idecabtagene vicleucel - Orphan - EMEA/H/C/004662/R/0029

Bristol-Myers Squibb Pharma EEIG

**Rapporteur:** Rune Kjeken, **Co-Rapporteur:** Heli Suila, **PRAC Rapporteur:** Ulla Wändel Liminga

**Scope:** 1 year Renewal of Marketing Authorisation, Opinion

**Action:** for adoption

The Rapporteur presented the assessment of the second 1-year renewal for Abecma. CAT adopted the 1-year renewal of the marketing authorisation.

#### 2.13.2. CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/MEA/007.1

Janssen-Cilag International NV

**Rapporteur:** Jan Mueller-Berghaus

**Scope:** Pharmacovigilance, Follow up MEA

Revised protocol of study No PCSONCA0014: Survey to evaluate the effectiveness of the ciltacabtagene autoleucel HCP Educational Program and the Product Handling Training.

The MAH is requested to consider a stratified randomisation approach in order to ensure that the acceptable number in each category of HCPs will complete the survey. A minimum number of participants should be proposed for physicians, nurses, pharmacists and wards on the one hand, and also for HCPs involved in prescribing vs handling of ciltacabtagene...
autoleucel in the selected countries. The estimations of effectiveness should also be performed separately, at least for HCPs involved in prescription, patient management and product handling in order to be able to interpret effectiveness in a meaningful way, as criteria for success and even the weighting of the questions is different. [From Initial MAA]

**Action:** for adoption

The outcome of the assessment was adopted.

### 2.13.3. Ebvallo - tabelecleucel - Orphan - EMEA/H/C/004577/REC/006

Pierre Fabre Medicament

Rapporteur: Egbert Flory

Scope: Quality, Opinion

**Action:** for adoption

The outcome of the assessment was adopted.

### 2.13.4. ROCTAVIAN - valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/R/0003

BioMarin International Limited

Rapporteur: Violaine Closson Carella, Co-Rapporteur: Silke Dorner, PRAC Rapporteur: Menno van der Elst

Scope: 1 year Renewal of Marketing Authorisation, Request for supplementary information

**Action:** for adoption

The Rapporteur presented the assessment of the first 1-year renewal for Roctavian. Some questions for clarification were raised. CAT adopted the request for supplementary information.

### 2.14. GMP and GCP inspections requests

No items

### 3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.
3.1. **Opinion**

3.2. **Day 60 Evaluation Reports**

3.3. **New Applications**

No items

4. **Scientific Recommendation on Classification of ATMPs**

Timetable:
- Start of the procedure: 21.04.2023
- EMA Coordinator’s draft report: 02.05.2023
- CAT Coordinator’s comments: 05.05.2023
- Revised scientific recommendation: 10.05.2023
- CAT’s discussion of scientific recommendation: 17.05.2023

4.1. **New requests – Appointment of CAT Coordinator**

4.1.1. **Living human adult allogeneic immunomodulatory progenitor (iMP) cells**

Treatment of myocardial scarring

Scope: Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

The CAT coordinator was appointed.

4.1.2. **Allogeneic viable natural killer (NK) cells CD56+ CD3-**

Treatment of patients with acute myeloid leukaemia (AML) who are in morphologic complete remission (CR) and for whom allogeneic haematopoietic stem cell transplantation (allo-HSCT) is not a suitable or preferred option

Scope: Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

The CAT coordinator was appointed.

4.1.3. **Recombinant Adeno-associated virus serotype 9 vector containing the human-lysosome-associated membrane glycoprotein 2 isoform B transgene**

Treatment of Danon disease

Scope: Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

The CAT coordinator was appointed.
4.2. **Day 30 ATMP scientific recommendation**

4.2.1. **Ixoberogene soroparvovec** (genetically engineered, replication-incompetent adeno-associated virus vector comprising the AAV.7m8 capsid proteins, carrying a version of complementary deoxyribonucleic acid for aflibercept)

Treatment of neovascular (wet) age-related macular degeneration

**Scope:** ATMP scientific recommendation

**Action:** for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.

4.2.2. **Ex vivo fused allogeneic human myoblasts (MB-N) with autologous human myoblast (MB-ALS)**

Treatment of amyotrophic lateral sclerosis (ALS)

**Scope:** ATMP scientific recommendation

**Action:** for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.

4.2.3. **Ex vivo fused allogeneic human myoblasts (MB-N) with autologous human bone marrow derived mesenchymal stem cells (MSC-ALS)**

Treatment of amyotrophic lateral sclerosis (ALS)

**Scope:** ATMP scientific recommendation

**Action:** for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.

4.2.4. **Ex vivo fused allogeneic human mesenchymal stem cell (MSC-N) with autologous human myoblast (MB-ALS)**

Treatment of amyotrophic lateral sclerosis (ALS)

**Scope:** ATMP scientific recommendation

**Action:** for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.
4.2.5. **Ex vivo fused allogeneic human myoblasts (MB-N1) with allogeneic human myoblasts (MB-N2)**

Treatment of amyotrophic lateral sclerosis (ALS)

**Scope:** ATMP scientific recommendation

**Action:** for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.

4.2.6. **Helper-dependent adenovirus vector coding for interleukin-1 receptor antagonist**

Treatment of osteoarthritis of the knee

**Scope:** ATMP scientific recommendation

**Action:** for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.

4.2.7. **Autologous CD34+ cells from mobilised peripheral blood**

Treatment of amyotrophic lateral sclerosis (ALS)

**Scope:** ATMP scientific recommendation

**Action:** for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.

4.2.8. **Biotinylated cultured reticulocytes, cultured from haematopoietic stem cells**

Treatment of red cell suppletion (e.g. trauma/anaemia)

**Scope:** ATMP scientific recommendation

**Action:** for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.

4.3. **Day 60 revised scientific recommendation (following list of questions)**

4.3.1. **Autologous chondrocytes cultured in hyaluronan-derived scaffold**

Repair of cartilage defects

**Scope:** ATMP scientific recommendation

**Action:** for discussion
CAT discussed the updated classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.

4.4. **Finalisation of procedure**

4.4.1. **Lyophilised supernatant of a pathogen inactivated and gamma sterilised platelet lysate**

Treatment of topical treatment of skin ulcers

Scope: European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

The classification report was adopted. The product does not fulfil the definition of an advanced therapy medicinal product as provided in Article 2(1) of Regulation (EC) No 1394/2007.

4.4.2. **Autologous intestinal organoid derived from adult stem cells from intestinal epithelial tissue**

Treatment of intractable ulcer

Scope: European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

The classification report was adopted. The product does fulfil the definition of a tissue engineered product as provided in Article 2(1) of Regulation (EC) No 1394/2007.

4.5. **Follow-up and guidance**

No items

5. **Scientific Advice**

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. **New requests - appointment of CAT Rapporteurs**

5.1.1. **Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers**

**Timetable:**

- Start of procedure at SAWP: 11-14.04.2023
- Appointment of CAT Peer Reviewers: 19-21.04.2023
- SAWP first reports: 02.05.2023
- CAT Peer Reviewer comments (NC/C) 05.05.2023
- CAT Peer Reviewer comments (Q) 10.05.2023
- Discussion at SAWP: 08-10.2023
- Discussion at CAT and feedback to SAWP: 15-17.05.2023

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:
- Start of procedure at SAWP: 13-16.03.2023
- Appointment of CAT Peer Reviewers: 22-24.03.2023
- SAWP first reports: 03.04.2023
- CAT Peer Reviewer comments (NC/C): 05.04.2023
- CAT Peer Reviewer comments (Q): 12.04.2023
- Discussion at SAWP: 11-14.04.2023
- Discussion at CAT and feedback to SAWP: 19-21.04.2023

5.2. Procedures discussed at SAWP – 1st reports, D40 JRIs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

No items

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:
Procedure start: 11-14.04.2023
SAWP recommendation: 12.05.2023
CAT recommendation: 17.05.2023
CHMP adoption of report and final recommendation: 25.05.2023

6.3.2. Month 1 – Discussion of eligibility
6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

Action: for information

7.1.2. Vote by proxy

Action: for information

7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Sweden presidency, 4 and 5 May 2023, Upsala (Sweden)

CAT: Lisbeth Barkholt, Maria Lüttgen
Scope: Topics for discussion at the upcoming SRLM
Action: for discussion
The final agenda of the upcoming SRLM was presented.

7.1.4. New timeschedule layout

CAT: Ilona Reischl
Scope: New layout of the timeschedule to capture all relevant information in a single location
Action: for discussion
EMA presented the new timeschedule layout, which aims to bring all relevant information together in a single excel file. CAT agreed to review it after a 4-month pilot.
CAT members to provide any comments or suggestions for further improvement to CAT Secretariat

7.2. Coordination with EMA Scientific Committees

None
7.3. **Coordination with EMA Working Parties/Working Groups/Drafting Groups**

7.3.1. **PRIME implementation of 5-year review recommendations – 2023 pilot features and guidance updates**

Scope: Summary of new features and their impact on CAT Rapporteurs

**Action:** for information

7.3.2. **Joint EU GCP inspectors-clinical assessors virtual workshop, 26 June 2023**

Scope: There will be a short presentation on the scope of the Joint EU GCP inspectors-clinical assessors virtual workshop organised by the subgroup of GCP inspectors and assessors working on embedding the outcome of GCP inspections into the benefit/risk assessment and modernisation of the inspection process. The presentation will also include a brief update on the deliverables of this subgroup.

**Action:** for information

CAT noted the information on the upcoming workshop. CAT members were asked to forward this information to the relevant colleagues in their agencies.

7.3.3. **Re-organisation of Biologics Working Party (BWP)**

Scope: BWP 3-year work plan and call for nominations

**Action:** for discussion

EMA informed CAT on the plan for Quality domain implementation. The end of the call for nominations for the BWP was noted (17.05.2023); the CAT Chair agreed to be part of the Quality Domain selection panel. Experts with quality (ATMP) expertise can be nominated by any CAT members for the Quality European Scientific Expert Community (ESEC).

7.4. **Cooperation with the EU regulatory network**

None

7.5. **Cooperation with international regulators**

7.5.1. **ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)**

CAT: Ilona Reischl

Scope: Feedback from the teleconference that was held on 13.04.2013

**Action:** for information

EMA provided feedback from the discussions at the last ATMP cluster TC.
7.6. **CAT work plan**

7.6.1. **Guideline of quality, non-clinical and clinical requirements for investigational ATMPs in clinical trials**

CAT topic leads: Ilona Reischl, Rune Kjeken, Claire Beuneu, Alessandro Aiuti

Scope: Comments received during the external consultation; discussion on the scope and content of the guideline

**Action:** for discussion

Ilona Reischl, on behalf of the drafting groups, informed CAT on the proposal for the structure of the guideline, the inclusion of a glossary and the potential extension of the scope to include guidance for novel products (e.g. genome editing). It will also be clarified in the guideline what will be the requirements for the clinical trial application versus development advice for the MAA.

The quality, non-clinical and clinical drafting groups will start reviewing the comments received during the public consultation (first drafting group meetings are scheduled for end of April/beginning of May). CAT will be kept informed of the progress of the drafting groups.

The feedback received from Finland and Sweden were briefly presented; CAT members can still provide observations to be taken into account by the drafting groups.

7.7. **Planning and reporting**

No items

7.8. **Others**

7.8.1. **CAT stakeholder meeting 2023**

CAT: Dariusz Sladowski, Ilona Reischl, Violaine Closson Carella, Carla Herberts

Scope: Topics proposed by the CAT stakeholders and plan of actions to prepare the agenda of the stakeholders meeting to take place on 16.05.2023

**Action:** for discussion

CAT agreed on the topics for discussion at the upcoming CAT stakeholder meeting. CAT members were appointed as speakers and/or moderators for the different topics. The stakeholder meeting will be a hybrid meeting, with part of the participant joining in person and part remotely (Webex).

7.8.2. **Euroscan – International HealthTechScan (i-HTS)**

CAT: Ilona Reischl

Scope: Feedback from the presentation by the CAT Chair on challenges in the field of ATMP in Europe at i-HTS Scientific meeting on ATMP4ALL – ‘How to raise awareness, equal access and trust in complex therapies in Europe?’
Action: for information
The CAT Chair presented the activities of EuroScan/i-HTS and the subgroup activities of ATMP4ALL, which are linked to health technology assessment (HTA)/reimbursement issues.

7.8.3. European Health and Digital Executive Agency (HaDEA)

CAT: Ilona Reischl
Scope: Update on HaDEA activities
Action: for information
The European Commission presented the role and activities of HaDEA. CAT members were encouraged to register themselves as experts to review project proposals.

8. Any other business

8.1. New Expert Management Tool
Scope: Presentation on the new Expert Management Tool to maintain a list of experts involved in medicines-related activities to collect their declarations of interests (eDoIs) and CVs
Action: for information
EMA provided a demonstration of the next expert management tool.

Date of next CAT meeting:
15-17 May 2023

9. List of participants
Including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 19-21 April 2023 meeting.

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Member State or affiliation</th>
<th>Outcome restriction following evaluation of e-DoI</th>
<th>Topics on agenda for which restrictions apply</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ilona Reischl</td>
<td>Chair</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Silke Dorner</td>
<td>Member</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Corina Spreitzer</td>
<td>Alternate</td>
<td>Austria</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Claire Beuneu</td>
<td>Member</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------</td>
<td>----------------------------</td>
<td>--------------------------------------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Rozalina Kulaksazova</td>
<td>Member</td>
<td>Bulgaria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Evelina Shumkova</td>
<td>Alternate</td>
<td>Bulgaria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Azra Selimovic</td>
<td>Member</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Rafaela Pontou</td>
<td>Member</td>
<td>Cyprus</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Isavella Kyriakidou</td>
<td>Alternate</td>
<td>Cyprus</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Kristyna Rehorova Hradilova</td>
<td>Alternate</td>
<td>Czechia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ebru Karakoc Madsen</td>
<td>Member</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Bibi Fatima Syed Shah</td>
<td>Alternate</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Toivo Maimets</td>
<td>Member</td>
<td>Estonia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Pille Saalik</td>
<td>Alternate</td>
<td>Estonia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Heli Suila</td>
<td>Member</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maija Tarkkanen</td>
<td>Alternate</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Violaine Closson</td>
<td>Member</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jean-Michel Race</td>
<td>Alternate</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jan Mueller-Berghaus</td>
<td>Member (CHMP co-opted member)</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Egbert Flory</td>
<td>Alternate (to CHMP representative)</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Gazouli</td>
<td>Member</td>
<td>Greece</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Angeliki Rompoti</td>
<td>Alternate</td>
<td>Greece</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Katalin Lengyel</td>
<td>Member</td>
<td>Hungary</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maura O'Donovan</td>
<td>Member</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Niamh Curran</td>
<td>Alternate</td>
<td>Ireland</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Concetta Quintarelli</td>
<td>Member</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Barbara Bonamassa</td>
<td>Alternate</td>
<td>Italy</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------------------</td>
<td>-----------------------------</td>
<td>---------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Raimondas Benetis</td>
<td>Alternate (to CHMP representative)</td>
<td>Lithuania</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Nancy De Bremaeker</td>
<td>Member</td>
<td>Luxembourg</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>John J. Borg</td>
<td>Member (CHMP member)</td>
<td>Malta</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Anthony Samuel</td>
<td>Alternate (to CHMP representative)</td>
<td>Malta</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Carla Herberts</td>
<td>Member (Vice-Chair)</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Babs Fabriek</td>
<td>Alternate</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Rune Kjeken</td>
<td>Member</td>
<td>Norway</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Dariusz Ślądowski</td>
<td>Member</td>
<td>Poland</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Maria Isabel Borba Vieira</td>
<td>Alternate (to CHMP representative)</td>
<td>Portugal</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Silviu Istrate</td>
<td>Member</td>
<td>Romania</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Katarina Vavrová</td>
<td>Member</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Margareta Fogelová</td>
<td>Alternate</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Metoda Lipnik-Stangelj</td>
<td>Member</td>
<td>Slovenia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Sol Ruiz</td>
<td>Member (CHMP co-opted member)</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Marcos Timón</td>
<td>Alternate (to CHMP representative)</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Lisbeth Barkholt</td>
<td>Member</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Lutgen</td>
<td>Alternate</td>
<td>Sweden</td>
<td>No participation in final deliberations and voting on:</td>
<td></td>
</tr>
<tr>
<td>Alessandro Aiuti</td>
<td>Member</td>
<td>Clinicians' Representative</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Alessandra Renieri</td>
<td>Alternate</td>
<td>Clinicians' Representative</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>--------------------------</td>
<td>----------------------------</td>
<td>-----------------------------</td>
<td>---------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Kerstin Sollerbrant</td>
<td>Member</td>
<td>Patients’ Representative</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Kieran Breen</td>
<td>Member</td>
<td>Patients’ Representative</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Hans Ovelgönne</td>
<td>Expert - via telephone*</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Torbjorn Callreus</td>
<td>Expert - via telephone*</td>
<td>Malta</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Christine Vaculik</td>
<td>Expert - via telephone*</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Rene Anour</td>
<td>Expert - via telephone*</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Bojana Divkovic</td>
<td>Expert - via telephone*</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Angelina Doriguzzi</td>
<td>Expert - via telephone*</td>
<td>Austria</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Florian Klinglmüller</td>
<td>Expert - via telephone*</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Christian Gartner</td>
<td>Expert - via telephone*</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Laura Rodríguez García</td>
<td>Expert - via telephone*</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Fernando Méndez</td>
<td>Expert - via telephone*</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Leire Aguado</td>
<td>Expert - via telephone*</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Macarena Rodríguez</td>
<td>Expert - via telephone*</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Concha Prieto</td>
<td>Expert - via telephone*</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>David Ordonez</td>
<td>Expert - via telephone*</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Esther Rincon</td>
<td>Expert - via telephone*</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jayne Crowe</td>
<td>Expert - via telephone*</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Nathalie Morgensztejn</td>
<td>Expert - via telephone*</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Andreea Barbu</td>
<td>Expert - via telephone*</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Peter Lohn</td>
<td>Expert - via telephone*</td>
<td>Sweden</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Tiina Holmberg</td>
<td>Expert - via telephone*</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
</tbody>
</table>

Meeting run with support from relevant EMA staff
10. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AAV: Adeno-Associated Virus
AR: Assessment Report
ATMP: Advanced Therapy Medicinal Product
BWP: Biologics Working Party
CAT: Committee for Advanced Therapies
CHMP: Committee for Medicinal Product for Human Use
COMP: Committee for Orphan Medicinal Products
CTFG: Clinical Trial Facilitation Group
DG: Drafting Group
EC: European Commission
EU NTC: European Union Network Training Centre
ERA: Environmental Risk Assessment
FDA: Food and Drug Administration
FL: Final Letter
GCG: Guideline Consistency Group
GCP: Good Clinical Practice
GLP: Good Laboratory Practice
GMO: Genetically-modified organism
GMP: Good Manufacturing Practice
GTMP: Gene Therapy Medicinal Product
HTA: Health Technology Assessment Bodies
HSPC: Hematopoietic Stem and Progenitor Cells
ITF: Innovative Task Force
JR: Joint Report
LoOI: List of outstanding issues
LoQ: List of questions
MA: Marketing Authorisation
MAA: Marketing Authorisation Application
MAH: Marketing Authorisation Holder
MNAT: Multinational assessment team
MSC: Mesenchymal stem cells
PDCO: Paediatric Committee
PMDA: Pharmaceuticals and Medical Devices Agency (Japan)
PIP: Paediatric Investigation Plan
PL: Package leaflet
Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1. to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft opinion at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:

The assessment of an application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a Day 120 list of questions (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (Ongoing evaluation procedures) (section 2.3). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.
Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Companion diagnostics (section 2.10)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, quality defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA’s committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

GMP and GCP Inspections Issues (section 2.14.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP.
Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

**Pre-Authorisation (section 6)**

*Paediatric Investigation Plan (PIP)*

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

*ITF Briefing meeting in the field of ATMPs*

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

*Priority Medicines (PRIME)*

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

**Organisational, regulatory and methodological matters (section 7)**

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

**Any other business (section 8)**

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)